| November 12, 2024
Genmab, a leading global biotechnology company specializing in next-generation antibody therapies for cancer and other serious diseases, has unveiled its ambitious new initiative—“AI Everywhere”—aimed at fully integrating artificial intelligence (AI) into its operations. This marks a significant leap toward utilizing AI not only to enhance research and drug development but also to optimize internal processes across the company.
Genmab’s AI Vision and Partnership with OpenAI
“We anticipate AI to contribute significantly to the quality of our science, decision-making, and efficiency in bringing medicines to patients,” said Tahi Ahmadi, Executive Vice President and Chief Medical Officer at Genmab. The company’s integration of AI began with the adoption of ChatGPT across operations, expanding from 1,000 to over 2,000 employees using ChatGPT Enterprise licenses. The tool is being deployed to assist in various tasks, from drafting documents to analyzing scientific data, offering employees a new way to work smarter and faster.
Empowering Employees with AI Tools
To help employees get started, Genmab encouraged its staff to ask ChatGPT, “What can you do to help me?” by sharing their job descriptions. This initiative led to transformative results, with employees reporting an average time saving of 3.5 hours per week. The use of ChatGPT is expected to fuel continuous learning and innovation, with the company investing in comprehensive training programs to ensure employees are equipped to make the most of AI.
Farhat Siddiqui, ChatGPT Product Manager at Genmab, noted, “Learning to use ChatGPT has been a transformative journey for our employees.” These tools are improving workflows, facilitating research, and simplifying tasks such as summarizing complex scientific literature.
Harnessing GPT-4 for Advanced Research
Genmab has already created over 100 custom GPTs tailored to specific tasks, including drafting clinical trial documents and summarizing medical content. The introduction of GPT-4o, which includes vision enhancements, has empowered Genmab to tackle previously impossible tasks, such as interpreting complex documents containing both images and text, drastically reducing time spent verifying references in medical publications.
Additionally, the company developed AI Translator GPT, a tool capable of translating intricate scientific documents with a level of accuracy previously achieved only by human translators. This has streamlined the translation process, cutting down the time it takes to translate from weeks to just hours or minutes. The tool also utilizes a unique reverse translation process to ensure quality and precision.
Hisham Hamadeh, Senior Vice President and Global Head of Data Sciences & AI at Genmab, emphasized that the partnership with OpenAI has been pivotal in unlocking the potential of AI. “Our partnership with OpenAI not only highlights Genmab’s commitment to innovation but also aims to unleash every colleague’s inner algorithmic leader to discover novel ways to leverage AI,” he said.
AI’s Growing Role in Biopharmaceutical Innovation
Genmab’s partnership with OpenAI allows the company to collaborate directly with AI experts, ensuring that both parties push the boundaries of what’s possible in biotechnology. As AI becomes more ingrained in the biopharmaceutical industry, models are expected to evolve, becoming even more powerful and capable of understanding and reasoning at unprecedented levels.
Scott Ogden, Head of Genmab’s AI Lab, shared the company’s vision: “Our vision goes beyond just streamlining processes; we’re aiming to fundamentally transform how we discover, develop, and deliver treatments to patients.”
Key Stats on Genmab’s AI Adoption:
- 100+ custom GPTs built and rolled out across the company
- 120 ChatGPT Enterprise conversations per user per week on average
- 3.5 hours of time saved per employee per week
Genmab’s commitment to integrating AI is setting a new standard for the biopharmaceutical industry, where the use of AI is expected to dramatically accelerate innovation and improve patient care outcomes.
To learn more about Genmab’s mission and AI innovations, visit Genmab’s official website.
